AE270FCD-9297-4185-B6CA-02062352DB66
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 13.600525624178712
- age_years
- 81
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.566
- E2F_TARGETS+0.517
- G2M_CHECKPOINT+0.443
- INTERFERON_GAMMA_RESPONSE+0.434
- DNA_REPAIR+0.417
- MYC_TARGETS_V2+0.324
- NOTCH_SIGNALING+0.324
- MYC_TARGETS_V1+0.281
- MITOTIC_SPINDLE+0.236
- IL6_JAK_STAT3_SIGNALING+0.208
Top 10 suppressed
- KRAS_SIGNALING_DN-0.330
- PANCREAS_BETA_CELLS-0.301
- HEDGEHOG_SIGNALING-0.252
- MYOGENESIS-0.252
- ANDROGEN_RESPONSE-0.219
- SPERMATOGENESIS-0.211
- ESTROGEN_RESPONSE_EARLY-0.189
- OXIDATIVE_PHOSPHORYLATION-0.170
- ESTROGEN_RESPONSE_LATE-0.148
- TNFA_SIGNALING_VIA_NFKB-0.144
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934909 | — | — | 0.816 |
| 2 | SRR934757 | — | — | 0.812 |
| 3 | 64F4FE1B-1B96-49CC-B4E9-454D971DB7BC | — | — | 0.810 |
| 4 | 22C1A41D-014D-4EFB-AF5B-EFC3FEC1E936 | — | — | 0.806 |
| 5 | SRR934919 | — | — | 0.802 |
| 6 | SRR934957 | — | — | 0.798 |
| 7 | 05699235-3F03-48C1-A78F-1C7966F38B56 | — | — | 0.797 |
| 8 | SRR934882 | — | — | 0.794 |
| 9 | 1A0F3795-92C5-4887-8CD0-B19C763CF6EF | — | — | 0.785 |
| 10 | 3F932445-1D8F-4128-A8DA-F36EA9F6E745 | — | — | 0.780 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.566 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.517 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.443 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.434 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.417 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.324 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.324 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.281 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.236 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.208 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.169 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.167 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.148 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.119 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.113 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.101 | Temsirolimus | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.092 | Inavolisib | — uncovered |
| APOPTOSIS | 0.088 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.086 | Idelalisib | — uncovered |
| PEROXISOME | 0.082 | Idelalisib | — uncovered |